Clinical Trial Update: BI 655066 Dose Ranging in Psoriasis, Active Comparator Ustekinumab [Phase 2]

View source ↗

Summary

Boehringer Ingelheim reported Phase 2 dose-ranging results for BI 655066 in psoriasis, with ustekinumab as an active comparator; results were posted after the s…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Psoriasis

Drugs mentioned

• BI 655066
• Stelara (ustekinumab)

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Psoriasis | Phase 2 | Status: COMPLETED | Results posted: 2016-09-19